Literature DB >> 365539

Effect of labetalol on plasma noradrenaline and adrenaline in hypertensive man.

N J Christensen, J Trap-Jensen, T L Svendsen, S Rasmussen, P E Nielsen.   

Abstract

Injection i.v. of labetalol, a new adrenergic alpha- and beta-blocking agent, decreased arterial blood pressure in 9 hypertensive subjects resting in the supine position, when standing and during supine exercise. Heart rate after labetalol was unchanged in the resting supine position, and it fell in the latter two conditions. Plasma noradrenaline concentration was higher after labetalol in all three experiments as compared to a control study. Plasma adrenaline after labetalol was increased only in the standing position, when the highest plasma noradrenaline concentrations were observed. Blood glucose concentration tended to increase after labetalol, but the difference was not statistically significant. The changes in plasma noradrenaline and blood glucose after labetalol mimic findings observed after alpha-adrenergic receptor blockade. The beta-adrenergic receptor blocking property of labetalol is responsible for the reduced heart rate and it is likely to contribute to the higher plasma noradrenaline concentration observed when standing and during supine exercise.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 365539     DOI: 10.1007/bf00560454

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Plasma catecholamines and arterial hypertension.

Authors:  N J Christensen
Journal:  Acta Med Scand Suppl       Date:  1976

2.  Effects of clonidine on biochemical indices of sympathetic function and plasma renin activity in normotensive man.

Authors:  L M Wing; J L Reid; C A Hamilton; P Sever; D S Davies; C T Dollery
Journal:  Clin Sci Mol Med       Date:  1977-07

3.  Plasma catecholamines and neurogenic hypertension.

Authors: 
Journal:  N Engl J Med       Date:  1977-07-07       Impact factor: 91.245

4.  Plasma noradrenaline and adrenaline in patients with thyrotoxicosis and myxoedema.

Authors:  N J Christensen
Journal:  Clin Sci Mol Med       Date:  1973-08

5.  A sensitive double-isotope derivative assay for norepinephrine and epinephrine. Normal resting human plasma levels.

Authors:  K Engelman; B Portnoy
Journal:  Circ Res       Date:  1970-01       Impact factor: 17.367

6.  The relationship between plasma catecholamine concentration and pulse rate during exercise and standing.

Authors:  N J Christensen; O Brandsborg
Journal:  Eur J Clin Invest       Date:  1973-07       Impact factor: 4.686

Review 7.  Isotope-derivative measurements of plasma norepinephrine and epinephrine in man.

Authors:  P E Cryer
Journal:  Diabetes       Date:  1976-11       Impact factor: 9.461

8.  Glucose-induced decrease in glucagon and pinephrine responses to exercise in man.

Authors:  H Galbo; N J Christensen; J J Holst
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1977-04

9.  Catecholamines and pancreatic hormones during autonomic blockade in exercising man.

Authors:  H Galbo; N J Christensen; J J Holst
Journal:  Acta Physiol Scand       Date:  1977-12

10.  Enhanced sympathetic nervous activity after intravenous propranolol in ischaemic heart disease: plasma noradrenaline splanchnic blood flow and mixed venous oxygen saturation at rest and during exercise.

Authors:  J F Hansen; B Hesse; N J Christensen
Journal:  Eur J Clin Invest       Date:  1978-02       Impact factor: 4.686

View more
  10 in total

1.  Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium.

Authors:  B N Prichard; D A Richards
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

2.  Effect of oral labetalol on plasma catecholamines, renin and aldosterone in patients with severe arterial hypertension.

Authors:  H J Kornerup; E B Pedersen; N J Christensen; A Pedersen; G Pedersen
Journal:  Eur J Clin Pharmacol       Date:  1979-11       Impact factor: 2.953

3.  Use of labetalol in hypertensive patients during discontinuation of clonidine therapy.

Authors:  T Rosenthal; B Rabinowitz; H Boichis; E Elazar; A Brauner; H N Neufeld
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

4.  Sympathetic nervous activity and the pressor effect of noradrenaline under chronic alpha-beta-adrenoceptor blockade with labetalol in hypertension.

Authors:  H Zschiedrich; W Neurohr; J B Lüth; T Philipp; A Distler
Journal:  Klin Wochenschr       Date:  1983-07-01

5.  Effect of labetalol, an alpha-and beta-adrenoceptor antagonist, on gastric acid and gastrin secretion in man.

Authors:  R Caldara; P Rampini; V Piepoli; M Borzoi
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

6.  Effect of indoramin, labetalol and alinidine on sympathetic function in normal man.

Authors:  D P Nicholls; J McNeill; P C O'Connor; D W Harron; W J Leahey; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1984-08       Impact factor: 4.335

7.  Beta-adrenoceptor blockade and psychic stress in man. A comparison of the acute effects of labetalol, metoprolol, pindolol and propranolol on plasma levels of adrenaline and noradrenaline.

Authors:  J Trap-Jensen; J E Carlsen; O J Hartling; T L Svendsen; M Tangø; N J Christensen
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

8.  Effects of chronic alpha and beta adrenoceptor blockade with labetalol on plasma catecholamines and renal function in hypertension.

Authors:  G Keusch; P Weidmann; W H Ziegler; R de Châtel; F C Reubi
Journal:  Klin Wochenschr       Date:  1980-01-02

9.  Circulatory and metabolic effects of a combined alpha- and beta-adrenoceptor blocker (labetalol) in hypertension of pregnancy.

Authors:  N O Lunell; P Hjemdahl; B B Fredholm; H Nisell; B Persson; J Wager
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

10.  Ventricular myosin pattern of spontaneously hypertensive turkeys is unaffected by labetalol treatment.

Authors:  P Pauletto; G Vescovo; G Scannapieco; A Angelini; L Dalla Libera; U Carraro; F Tessari; C Dal Palù
Journal:  Basic Res Cardiol       Date:  1988 May-Jun       Impact factor: 17.165

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.